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Introduction: Luminal, estrogen receptor-positive (ER+) breast cancers can metastasize but lie dormant for years
before recurrences prove lethal. Understanding the roles of estrogen (E) or progestin (P) in development of luminal
metastases or in arousal from dormancy is hindered by few preclinical models. We have developed such models.
Methods: Immunocompromised, ovariectomized (ovx’d) mice were intracardiac-injected with luminal or basal
human breast cancer cells. Four lines were tested: luminal ER+PR+ cytokeratin 5-negative (CK5−) E3 and MCF-7 cells,
basal ER−PR−CK5+ estrogen withdrawn-line 8 (EWD8) cells, and basal ER−PR−CK5− MDA-MB-231 cells. Development
of micrometastases or macrometastases was quantified in ovx’d mice and in mice supplemented with E or P or
both. Metastatic deposits were analyzed by immunohistochemistry for luminal, basal, and proliferation markers.
Results: ER−PR− cells generated macrometastases in multiple organs in the absence or presence of hormones. By
contrast, ovx’d mice injected with ER+PR+ cells appeared to be metastases-free until they were supplemented with
E or E+P. Furthermore, unlike parental ER+PR+CK5− cells, luminal metastases were heterogeneous, containing a
significant (6% to 30%) proportion of non-proliferative ER−PR−CK5+ cells that would be chemotherapy-resistant.
Additionally, because these cells lack receptors, they would also be endocrine therapy-resistant. With regard to
ovx’d control mice injected with ER+PR+ cells that appeared to be metastases-free, systematic pathologic analysis of
organs showed that some harbor a reservoir of dormant micrometastases that are ER+ but PR−. Such cells may also
be endocrine therapy- and chemotherapy-resistant. Their emergence as macrometastases can be triggered by E or
E+P restoration.
Conclusions: We conclude that hormones promote development of multi-organ macrometastases in luminal
disease. The metastases display a disturbing heterogeneity, containing newly emergent ER−PR− subpopulations
that would be resistant to endocrine therapy and chemotherapy. Similar cells are found in luminal metastases of
patients. Furthermore, lack of hormones is not protective. While no overt metastases form in ovx’d mice, luminal
tumor cells can seed distant organs, where they remain dormant as micrometastases and sheltered from therapies
but arousable by hormone repletion. This has implications for breast cancer survivors or women with occult disease
who are prescribed hormones for contraception or replacement purposes.* Correspondence: ndiya.ogba@ucdenver.edu
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Luminal breast cancers represent over 70% of cases [1].
At least 1% of their cells express estrogen (ER+) or pro-
gesterone (PR+) receptors or both [2], driving estrogen
(E)-dependent growth. Despite progress toward early
diagnoses and advances in treatment, 20% to 30% of all
patients with breast cancer and 40% to 50% of patients
with luminal breast cancer experience relapses that in-
clude distant metastases [3,4]. This tends to occur within
the first 5 years for patients with basal-like ER−PR− or
HER2+ disease and later for patients with luminal dis-
ease [5]. In one study, median 15-year distant relapse
rates were 27.8% for luminal A and 42.9% for luminal B
[5]. Because molecular properties of primary tumors may
be preserved in metastases [6], adjuvant endocrine therap-
ies can improve initial survival rates even in patients with
advanced luminal disease [7]. Nevertheless, the survival
curve for luminal disease declines steadily after 5 years,
overtaking more aggressive breast cancer subtypes after
about 15 years [5,8]. Therefore, since they represent the
most common forms of the disease, luminal tumors are re-
sponsible for most breast cancer deaths. Explanations for
prolonged luminal tumor dormancy and their slow but in-
exorable recurrence and lethality remain unclear, and roles
of cellular heterogeneity and hormones in this process, if
any, are poorly understood.
The Women’s Health Initiative (WHI) report on post-
menopausal hormone replacement therapy (HRT) showed
that the risks of combined E plus progestin (P), unlike
those of physiological E alone, outweighed the benefits [9].
Widespread acceptance of the WHI data led to a general
decrease in HRT use. Concurrent reductions in the inci-
dence of invasive luminal cancers indirectly validated the
WHI conclusions [10]. However, explanations for the dele-
terious effects on the breast of physiological E and P in
combination HRT remain unclear partly because hormonal
effects on carcinogenesis versus proliferation are often con-
flated, and the term “risk” intimates that the hormones are
causative. P appears to have no effect on long-term tumor
growth in vivo [11] but expands normal adult mammary
stem cells and cancer stem cells [12-14]. Regarding WHI,
we therefore postulated that for E+P, the P component, in
a non-proliferative step, reactivates cancer stem cells in
pre-existing but undiagnosed, perhaps dormant, disease
[15]. That said, little is known about the roles of E and P in
metastasis and recurrence from dormancy.
Clinically, the major sites of luminal metastases are bone
(>49%), followed by pleura/peritoneum, liver and lung
(~20%), distant nodes (~14%), and brain (6%) [5]. The ER
and PR status of the primary tumor may be reflected in
bone metastases [5,16], explaining the use of endocrine
therapies to treat disseminated disease that is rarely reana-
lyzed for biomarker expression. Few solid tumor models
exist for detailed studies of luminal metastases and theirhormone regulation. One interesting new model uses seri-
ally transplanted patient-derived luminal tumor xeno-
grafts, three of which demonstrate E-dependent growth
and retain luminal markers and gene expression profiles
[17]. The xenografts metastasize to lungs and lymph
nodes (LNs) [17], but the role of hormones, if any, in
tumor-cell dispersal is unclear. Lacking efficient solid
tumor models, a recent study used systemically injected
ER+PR+ MCF-7 cells to show that they can generate me-
tastases in an E-dependent manner but that the initial
homing and seeding steps with development of micro-
metastases do not require E [18]. Additionally, two dor-
mancy models that included luminal cells were recently
described [19,20]. However, they do not address the role
of hormones in metastasis or recurrence [4].
We previously demonstrated that in E-replete states,
ER+PR+ orthotopic xenografts metastasize to distant LNs
and occasionally to other organs [21]. Detailed immunohis-
tochemistry (IHC) analyses of such tumors showed that
during their expansion in mice, initially pure ER+PR+ cells
develop cellular heterogeneity. At necropsy, presumptive
“luminal” tumors contain at least one cell subpopulation
we call “luminobasal” that is ER−PR− and expresses cyto-
keratin 5 (CK5), a protein usually associated with basal-like
cancers [11,13,22]. In clinical samples of luminal disease,
similar basal-like, ER−PR−CK5+ cells, whose numbers in-
crease with hormone therapies, can be found [23]. These
hormone-resistant, possibly chemo-resistant cells are likely
to have a poor prognosis. The heterogeneity raises ques-
tions about the identity of cell subpopulations in primary
luminal disease that are responsible for metastatic engraft-
ment and growth.
In this study, we develop a luminal metastases model
and assess the role of E and P in metastatic engraftment
and recurrence from dormancy. To short-circuit the
cellular heterogeneity issue and study engraftment by
each cell population independently, T47D-derived solid
tumor xenografts were partitioned into their luminal
(called E3) and luminobasal (called EWD8) subpopula-
tions [22]. These, plus established luminal (MCF-7) and
basal (MDA-MB-231) breast cancer cell lines, were tagged
with luminescent and fluorescent markers for in vivo and
ex vivo analyses. Cells were injected into the left ventricle
of ovariectomized (ovx’d) immunocompromised mice,
and their colonization and proliferation in distant organs
was monitored in the absence of hormones or following E
or E+P repletion. We found that luminobasal and basal
cells generate metastases regardless of the hormonal state.
In contrast, luminal cells rarely form metastases unless E
or E+P is restored. The organs colonized by luminal and
basal cells are similar and mimic the clinical pattern,
dominated by bone. Despite initial injection of in vitro
pure luminal cells, their metastases in vivo exhibit cellu-
lar heterogeneity, including outgrowth of ER−PR−CK5+
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slowly than surrounding luminal cells. Notably, although
luminal cells seldom generate macrometastases in the ab-
sence of hormones, viable dormant micrometastases en-
graft at distant sites. If mice harboring such occult tumor
cells are subsequently hormone supplemented, overt me-
tastases materialize.
Materials and methods
Cell lines
MCF-7 human breast cancer cells were from Sam Brooks
(Michigan Cancer Foundation); T47D cells were from Iafa
Keydar (Tel Aviv University, Israel). The T47Dco subline
described in Horwitz et al. [24] has low ER and exception-
ally high PR that are not absolutely E-dependent. As de-
scribed [22], E3 and EWD8 are sublines of T47Dco. The
cell lines were derived from solid tumor xenografts grown
in ovx’d NSG (non-obese diabetic/severe combined im-
munodeficient gamma) mice either without (E withdrawn,
EWD) or with 17β-estradiol (E) supplementation. By gene
profiling, E3 cells cluster with luminal cell lines and
EWD8 cells cluster with basal-like triple-negative (TN)
cell lines [22]. Their T47Dco origin was confirmed by
short tandem repeat (STR) and karyotype analyses; their
luminal versus basal-like classification and isogenicity
were demonstrated by gene expression profiling [22].
BT-474 and MDA-MB-231 cells were from the ATCC
(Manassas, VA, USA). These cells were also authenti-
cated by STR analysis. All cells are mycoplasma-free.
To track metastases at necropsy, cells were tagged
with ZsGreen (ZsG) by retroviral infection [21]. To quan-
tify metastatic burden in living mice, cells were also modi-
fied to express luciferase. For this, pMSCV-Luciferase
PGK-hygro (gift of Heide Ford, University of Colorado)
was transfected into PT-67 packaging cells. ZsG-tagged
cells were incubated in filtered, virus-containing superna-
tants and selected for hygromycin resistance. Luciferase
expression was confirmed with a kit (Promega, Fitchburg,
WI, USA). EWD8 cells were cultured in phenol red-free
minimum essential medium (MEM) and 5% fetal bovine
serum (FBS) depleted of hormones by incubation with
dextran-coated charcoal pellets followed by filtration [22].
E3 cells were cultured in the same medium supplemented
with 10 nM E. MCF-7 and MDA-MB-231 cells were
grown as described [22].
Intracardiac injections and metastases quantification
Animal protocols were approved by the University of
Colorado Institutional Animal Care and Use Committee.
Female NSG mice were ovx’d at 3 to 4 weeks (The
Jackson Laboratory, Bar Harbor, ME, USA). Six-week-
old mice were anesthetized with isoflurane and injected
in the left ventricle with 105 tumor cells suspended in
0.1 mL phosphate-buffered saline by using a 26G needleguided by ultrasound imaging (Vevo770; VisualSonics,
Toronto, ON, Canada). Mice (10 or more per group)
were implanted subcutaneously with silastic pellets con-
taining 10 mg cellulose (C), 2 mg E + 8 mg cellulose (E),
2 mg C + 8 mg progesterone (P), or 2 mg E + 8 mg pro-
gesterone (E+P) that we previously showed release hor-
mones at physiological levels for premenopausal women
[11]. Body weights were recorded weekly. To switch
from C to hormones after 8 weeks, mice were anesthe-
tized and cellulose pellets were excised and replaced
with C, E, P, or E+P-releasing pellets. Development and
progression of metastases were quantified weekly by
bioluminescent imaging with Xenogen in vivo imaging
systems (IVIS) 200 (Caliper Life Sciences, Hopkinton,
MA, USA) to capture photon flux, after anesthetized mice
were intraperitoneally injected with 75 mg/kg D-Luciferin.
Signal intensity was quantified with Living Image 2.60.1
software (Caliper Life Sciences). Mice were euthanized if
imaging showed extensive metastases or at signs of
morbidity. At necropsy, organs with ZsG fluorescent me-
tastases were found by using UV light (Illumatool 9900;
Lightools Research, Encinitas, CA, USA) coupled to a
dissecting microscope (SZ-61; Olympus, Tokyo, Japan)
and photographed with a digital camera (Olympus C-
5050). Organs with ZsG fluorescence were collected
and processed for IHC [21]. Additionally, apparently
metastasis-free non-fluorescent organs, including lungs,
liver, adrenals, LNs, and long bones, were harvested
from mice in the C group.Three-dimensional colonies and histology
Briefly [25], for three-dimensional (3D) colonies, 4 × 104
E3 or MCF-7 cells were plated into 8-well chambered
slides (BD Biosciences, East Rutherford, NJ, USA) pre-
coated with 60 μL growth factor-reduced phenol red-free
Matrigel. Colonies were grown 1 week in phenol red-free
MEM with 5% charcoal-stripped FBS, without hormones
(C/ethanol, 1:1,000 vol/vol) or with E (10 nM), or E and P
(100 nM), in media refreshed every 2 days. Matrigel blocks
were embedded in Histogel (Richard-Allen Scientific, part
of Thermo Fisher Scientific, Waltham, MA, USA), fixed
overnight in 4% paraformaldehyde, switched to 70% (vol/
vol) ethanol, and paraffin-embedded. Mouse organs were
also fixed in 4% paraformaldehyde and processed as above.
Bone samples were decalcified in 10% EDTA for 1 week
prior to fixation. Paraffin-embedded samples were sec-
tioned (4 μm) serially, deparaffinized in xylene, and
rehydrated in graded alcohol. To locate micro- or
macrometastases, every 5th or 10th section was stained
with hematoxylin and eosin (H&E) until tumor cells ap-
peared microscopically, after which continuous sections
were saved for IHC. In some studies, CK8/18 IHC re-
placed H&E.
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For antigen retrieval, slides were heated in citrate buffer
and sections were blocked 1 hour in 10% normal goat
serum. Primary antibodies, including clones and concen-
trations or dilutions, are listed in Table S1 (Additional
file 1). These were detected either with fluorescent sec-
ondary antibodies conjugated to AlexaFluor-488 or -555
(1:200, Invitrogen, Waltham, MA, USA) and counter-
stained with 4′,6-diamino-2-phenylindole (DAPI) or with
horseradish peroxidase-labeled secondary antibodies and
DAB+ chromogen/substrate (Dako, Glostrup, Denmark).
Slides were imaged with a Nikon Eclipse E600 microscope
(Nikon, Tokyo, Japan) equipped with a CoolSnap fx cam-
era (Photometrics, Tucson, AZ, USA) operated by Image-
Pro software (Media Cybernetics, Rockville, MD, USA)
[22]. For CK5, phosphor-histone H3 (pHH3) and nuclear
proliferation marker (Ki67) quantification, photographs of
at least five random 40× fields (3D colonies) or 100× fields
(xenografts) per condition were used to calculate values.
Clinical
Seventy-two primary tumors and matching metastases
were collected from the archives of the Department of
Pathology, Helsinki University Hospital, Finland, with
approval from the ethics committee of the Helsinki
University Central Hospital and with patient consent.
Clinicopathological and other data have been published
[26,27]. Brain metastases from four patients were cut into
4-micron sections and stained by dual colorimetric IHC
(Envision G/2 Doublestain; Dako) for PR (NeoMarkers,
Freemont, CA, USA) and CK5 (Novocastra, Leica
Biosystems, Nussloch, Germany) [22].
Statistical analysis
Data are reported as mean ± standard error of the mean
(SEM) of three or more independent experiments and
were analyzed statistically with Prism v6.0 (GraphPad
Software, La Jolla, CA, USA) by Student’s t test. Differences
in survival curves among treatment groups were per-
formed by using Kaplan-Meier semi-parametric method
with the log-rank test. P values of less than 0.05 were con-
sidered statistically significant.
Results
Hormones promote metastasis of ER+PR+ breast cancer
cells
To analyze effects of ovarian hormones on metastases,
ovx’d NSG mice implanted with control cellulose (C), E, or
E+P-releasing pellets [11] were intracardiac (IC)-injected
into the arterial circulation with 105 tumor cells. Two
luminal ER+PR+CK5− (E3 and MCF-7) and two basal-like
(EWD8 and MDA-MB-231) cell lines were compared.
EWD8 are TN ER−PR−HER2− but CK5+EGFR+ [22];
MDA-MB-231 are TN and CK5−EGFR+ [28]. Comparisonsbetween E3 and EWD8 are especially useful since they are
isogenic “twins”, having been derived from the same lu-
minal parental cells [22]. All cells were modified to express
luciferase and ZsG. To confirm cell subtype assignment
prior to IC injections, the cells were grown as 3D colonies
in phenol red-free Matrigel and analyzed for luminal and
basal markers (Additional file 2). E3 cells are ER+PR+;
MCF-7 cells are ER+PR− in phenol red-free medium (but
PR can be induced by E [29]). Both are CK5− and vimen-
tin−. EWD8 cells lack luminal markers and are CK5+
vimentin−; MDA-MB-231 cells lack luminal markers and
are CK5−vimentin+.
Progression of metastases in hormone-free or hormone-
replete mice was quantified weekly by whole-body
bioluminescent luciferase imaging (BLI). Basal-like ER−
PR− EWD8 cells were highly aggressive, producing exten-
sive metastases within 20 days in the absence of hormones
(C) (Figure 1A, B). Although E and E+P appear to acceler-
ate EWD8 metastasis, the effects are not statistically sig-
nificant (C versus E, P = 0.857; C versus E+P, P = 0.819)
(Figure 1A). Mice had to be sacrificed after about 30 days.
In contrast, mice injected with isogenic luminal ER+PR+
CK5− E3 cells appeared to be metastasis-free in the ab-
sence of hormones (C) up to the study termination of
80 days (Figure 1A). However, if E3-injected mice were
supplemented with E or E+P starting on day 0, metastases
began to develop after more than 28 days and the tumor
burden increased weekly thereafter (Figure 1A, B). E-
supplementation significantly (P <0.05) increased tumor
burden relative to C, and addition of P to E exacerbated
this (P <0.005).
As surrogates for overall health, mouse body weights
were also monitored (Additional file 3A). Control (C) mice
with EWD8 metastases lost weight rapidly, appeared sickly
after 20 days, and were sacrificed early. C mice injected
with E3 cells gained weight; ones receiving E or E+P
maintained starting weights for up to 80 days. These data
are reflected in metastasis-free survival as estimated by
Kaplan-Meier plots (Figure 1C) with median survival of
30 days for EWD8 mice regardless of hormonal state,
which is significantly (P = 0.003) less than the 65- to 70-
day median survival for E3 mice on E or E+P, and the in-
definite survival of control E3 mice.
To test a second luminal cell line, MCF-7 cells were IC
injected into ovx’d mice without (C) or with E or E+P sup-
plementation (Figure 1D). Like E3 cells, MCF-7 cells failed
to produce metastases in the absence of hormones, but
metastases were evident after 20 days in E- or E+P-supple-
mented mice. Compared with E3 cells, MCF-7 cells are
more sensitive to E. In the presence of hormones, the
MCF-7 metastatic burden increased progressively until the
study was terminated at 45 days. Body weights remained
relatively stable under all conditions (Additional file 3B).
In sum, two different luminal breast cancer cell lines
Figure 1 Hormones are necessary for luminal tumor metastases. (A) Ovariectomized (Ovx’d) non-obese diabetic/severe combined
immunodeficient gamma (NSG) mice were intracardiac (IC)-injected with 105 luciferase and ZsGreen-tagged basal-like estrogen withdrawn-line 8
(EWD8) or luminal E3 cells, and implanted with cellulose control (C) or with estrogen (E) or estrogen + progestin (E+P)-releasing pellets. Weekly
quantitation used in vivo bioluminescent imaging (BLI). Data are presented as mean ± standard error of the mean (SEM) of BLI signal (n = 20 per
treatment group). *P <0.05, **P <0.005, Student’s t test. (B) Representative luciferase BLI whole-body images. (C) Kaplan-Meier survival curves
(n = 20 per treatment group); P = 0.003, log-rank test. (D) Ovx’d NSG mice were IC injected with 5 × 105 luciferase and ZsGreen-tagged luminal
MCF-7 cells and implanted with C, E, or E+P pellets. Weekly in vivo luciferase BLI quantitation. Data are presented as mean ± SEM of BLI signal
(n = 20 per treatment group). *P <0.05, Student’s t test.
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mised mice demonstrate that metastasis is promoted by
ovarian hormones (Figure 1). In contrast, formation of
metastases from basal-like cells is largely hormone-
independent. Taken together, these data suggest that
major effects of E or E+P are on the malignant luminal
cells. This may be further modified by effects of hormones
on the metastatic niche.
Hormones promote luminal metastasis in multiple organs
Clinically, major sites of metastases are bones, liver, and
lungs [5,30]. ZsGreen fluorescence at necropsy (Figure 2A)
was used to track the organ specificity of metastatic cells.
In hormone-replete (but not hormone-deprived) mice, lu-
minal E3 (Figure 2B) and MCF-7 cells (Additional file 4A)
colonize multiple organs, including bones, liver, lungs,
brain, adrenals, and LNs. Quantitation of the organ sites
colonized indicate that E enhances the incidence of metas-
tases (blue bars), which is not significantly altered by P
(red bars) (Figure 2B and Additional file 4A). Overall, in
the absence of hormones (green bars), the frequency of E3
and MCF-7 bone metastases in C mice is less than 2% but
averages 65% in E- or E+P-replete mice. Luminal metasta-
ses to some organs (adrenals, for instance) exhibit some
independence from exogenous hormones (Figure 2B and
Additional file 4A) possibly because of endogenous steroidhormone biosynthesis [31]. Basal-like EWD8 (Figure 2C)
or MDA-MB-231 cells (Additional file 4B) are highly ag-
gressive and do not require hormones to form multi-
organ metastases. In the case of bones, for example,
basal cells formed metastases at 80% or greater fre-
quency in both C and hormone-treated mice (Figure 2C
and Additional file 4B).
Among the four cell lines, minor organ-specific differ-
ences were observed: Liver metastases were lower for E3
than MCF-7 cells, and abdominal/intestinal, mammary
gland LN, renal, and uterine metastases were higher for
E3 than MCF-7 cells (Figure 2B and Additional file 4A).
Also, brain metastases were lower for EWD8 than for
MDA-MB-231 cells (Figure 2C and Additional file 4B).
Nonetheless, the number of metastatic sites observed for
each cell line demonstrates the critical role of hormones
(especially E) for metastases by luminal E3 and MCF-7
cells and the hormone independence for metastases by
basal-like EWD8 and MDA-MB-231 cells.
Cellular heterogeneity in luminal and basal metastases
Over 70% of patients with breast cancer succumb to lytic
bone lesions that cause fractures, pain, and associated
complications [32]. Since clinically, metastases can con-
tain cells that differ from those at the primary site [33],
experimental bones were sectioned and analyzed by
Figure 2 Hormones control metastases of luminal but not basal-like tumor cells. (A) Ovariectomized (Ovx’d) non-obese diabetic/severe
combined immunodeficient gamma (NSG) mice were intracardiac-injected with 105 luciferase and ZsGreen-tagged basal-like EWD8 or luminal E3
cells and implanted with cellulose (C) or with estrogen (E) or estrogen + progestin (E+P)-releasing pellets. Representative images at necropsy
of ZsG fluorescent metastases in different organs are shown. BF, bright field image (n = 20 per treatment group). (B) Bar graph shows the
percentage of mice in each treatment group—C (green), E (blue), and E+P (red)—with E3 metastases to distant organs. Data are presented as
mean percentages per group (n = 20 per treatment group). (C) Bar graph shows the percentage of mice in each treatment group—C (green), E
(blue), and E+P (red)—with EWD8 metastases to distant organs. Data are presented as mean percentages per group (n = 20 per treatment group).
(D) Number of ZsG+ metastatic sites per mouse at necropsy for E3 and EWD8 cells under C (green), E (blue), or E+P (red) conditions. Data are
presented as mean ± standard error of the mean (SEM) (n = 20 per treatment group). **P <0.005, Student’s t test.
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injected with luminal E3 or MCF-7 yielded no tumor
cells (Figure 3A) confirming the necropsy data. However,
more than 50% of bones in E- or E+P-supplemented mice
contained tumor cells (Figure 3B). These were generally
found in long bones and spine, and were characterized by
islands of malignant cells infiltrating the marrow space,
associated with variable bone destruction.
Unlike the homogeneous ER+PR+CK5− luminal state of
E3 and MCF-7 cells at the time of injection (Additional
file 2), bone metastases are heterogeneous (Figure 3B,
middle and lower panels), consisting not only of the ex-
pected ER+PR+ luminal cells (green nuclei) but also of
multiple basal-like ER−PR−CK5+ luminobasal cells (red
cytoplasm) [22]. E3 metastases contained about 8% lumi-
nobasal cells in the presence of E, which were significantly
(P = 0.037) increased to about 18% by addition of P to E
(Figure 3C, top panel). MCF-7 metastases contained
high levels of luminobasal cells (25% to 30%) in both E
and E+P (Figure 3C, bottom panel).
Although hormone-dependent acquisition of hetero-
geneity is not observed for cells grown on plastic, it can
be studied in 3D colony assays (Additional file 5). For in-
stance, E3 colonies contain 0% CK5+ cells in E and 14%CK5+ cells in E+P. MCF-7 colonies contain about 3%
CK5+ cells in E or E+P. Differences between colony as-
says and in vivo metastases may be due to signals con-
tributed by the metastatic niche.
Detailed marker analyses of luminal E3 and MCF-7
bone metastases are shown in Additional file 6A and B.
The ER−PR− subpopulation loses the luminal markers
CK8/18 and claudin 3 (CLD3) and is HER2− (unlike BT-
474 controls). Luminal bone metastases also lack the
mesenchymal marker vimentin, unlike basal-like MDA-
MB-231 metastases that retain vimentin (Additional
file 6A and B).
Basal-like EWD8 and MDA-MB-231 cells also colonize
bone but do so even in the absence of hormones
(Additional file 7A). Histopathology again shows malig-
nant epithelial cells infiltrating the marrow with bone
destruction; EWD8 infiltrates also show signs of desmo-
plasia (Additional file 7A, top H&E panel). Receptor
conversion in clinical cases has been reported [34,35].
Because EWD8 cells have luminal parentage [22], we
looked for reversions by using ER and PR as markers.
However, EWD8 metastases uniformly retain the basal
marker CK5 and are ER−, PR−, and vimentin− (Additional
file 7A). A “double negative” ER−PR−CK5− subpopulation
Figure 3 Homogeneous ER+PR+CK5− luminal E3 and MCF-7 cells
generate heterogeneous bone metastases containing ER−PR−
CK5+ luminobasal cells. (A) Representative hematoxylin and eosin
(H&E) and immunohistochemistry (IHC) of control (C) bones lacking
metastases despite intracardiac (IC) injection of E3 or MCF-7 cells.
H&E: (B) bone, (BM) marrow. Scale bars: 50 μm. IHC: estrogen
receptor (ER) or progesterone receptor (PR) (green), cytokeratin 5
(CK5) (red), and 4′,6-diamino-2-phenylindole (DAPI) (blue) by
immunofluorescent (IF) staining (n = 5 per group). Scale bars: 20 μm.
(B) H&E and IHC of E- or E+P-treated mice with bones containing
metastases after IC injection of E3 or MCF-7 cells. H&E: bone (B) and
tumor (T) cells (n = 5 per group). Scale bars: 50 μm. IHC: ER or PR
(green), CK5 (red) and DAPI (blue) by IF staining (n = 5 per group).
Scale bars: 20 μm. (C) Percentage of CK5+ cells in E- or E+P-treated
E3 and MCF-7 bone metastases. Mean ± standard error of the mean
(SEM) values are shown (n = 5 per group). *P <0.05, Student’s t test.
(D) Proliferation rates of CK5+ and CK5− cells measured by
phosphor-histone H3 (pHH3) in E- and E+P-treated E3 and MCF-7
bone metastases. Mean ± SEM values are shown (n = 5 per group).
**P <0.005, Student’s t test.
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cells resemble MDA-MB-231 metastases with regard to
CK5 loss, but unlike MDA-231 cells, they lack vimentin
(Additional file 7A). These analyses demonstrate interesting
cellular heterogeneity even within basal-like metastases.In previous studies of primary luminal cancers, we
showed that the ER+PR+ population suppresses mitosis
of the ER−PR− subpopulation [23]. The latter would
therefore be both hormone-resistant because of a lack of
receptors and chemotherapy-resistant because of quies-
cence [23]. To assess proliferation of cell subpopulations
in our models, sections of E3, MCF-7, and EWD8 bone
metastases from E- or E+P-treated mice were dual-stained
for CK5 and the mitosis marker pHH3 [36]. We find that
regardless of the hormone state, in both E3 and MCF-7
bone metastases (Figure 3D), the ER−PR−CK5+ luminobasal
(LB) subpopulation is significantly (P <0.005) growth-
suppressed compared with its ER+PR+CK5− luminal (LUM)
neighbors. In EWD8 bone metastases (Additional file 7B),
growth of the pre-existing CK5+ population is significantly
(P <0.005) reduced compared with the newly formed
double-negative ER−PR−CK5− subpopulation. In sum, in
addition to marker heterogeneity, cell growth is hetero-
geneous in metastases, making therapy difficult.
Additional file 8A shows brain metastases caused by
E3 and MCF-7 cells. Like bone, brain metastases are het-
erogeneous, containing both the injected ER+PR+CK5−
luminal population (green) and the newly arisen ER−PR−
CK5+ luminobasal subpopulation (red). Therefore, this
phenotypic conversion is not organ-specific. Similar cellu-
lar heterogeneity marks luminal metastases of patients as
shown in a clinical sample of brain metastases (Additional
file 8B) [27]. Overall, these data demonstrate that injection
of apparently homogeneous tumor cells generates metas-
tases with heterogeneous cell populations, partly in re-
sponse to hormones. Furthermore, these subpopulations
can exhibit divergent proliferation rates.
Luminal tumor dormancy and reactivation by hormones
Our models demonstrate that IC-injected malignant
luminal cells form macrometastases in hormone-
supplemented but not in hormone-free ovx’d mice.
What happened to the disseminated tumor cells injected
into hormone-free mice? To address this, hormone-free
ovx’d C mice were IC-injected with 105 Luc/ZsG-E3 or
Luc/ZsG-MCF-7 cells and monitored for 8 weeks by IVIS
(Figure 4A). Few metastases were imaged by IVIS despite
the fact that 8 weeks is more than sufficient for these to
be visible in hormone-supplemented mice (Figure 1A,
1D). At 8 weeks, the C pellets were removed and replaced
with C, E, P, or E+P-releasing pellets, and mice were
monitored for another 8 weeks. As shown for E3 injected
mice (Figure 4A), under C or P-restored conditions, mice
remained metastases-free. However, metastases emerged
in E- or E+P-restored mice. Results from IVIS imaging
were confirmed at necropsy (Figure 4B), with few E3
ZsG+ fluorescent deposits after 16 weeks in organs of C
(1/11; 9%) or P-treated mice (1/15; 6%) but robust ZsG+
metastases in one or more organs of E (8/16; 50%) or
Figure 4 (See legend on next page.)
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Figure 4 Hormones reactivate dormant luminal micrometastases. (A) Ovariectomized (Ovx’d) non-obese diabetic/severe combined
immunodeficient gamma (NSG) mice were intracardiac (IC)-injected with 105 luciferase- and ZsG-tagged E3 cells without hormone supplementation
(cellulose, or C) and monitored for 8 weeks. At week 8, the C pellet was removed and replaced with C (n = 11), estrogen (E) (n = 16), progestin
(P) (n = 15), or estrogen + progestin (E+P) (n = 17)-releasing pellets for another 7 to 8 weeks. Weekly bioluminescent luciferase imaging (BLI)
imaging in live mice by in vivo imaging systems (IVIS). Data are presented as mean ± standard error of the mean (SEM) of BLI signal. *P <0.05,
**P <0.005, Student’s t test. (B) Bar graph shows the percentage of mice in each treatment group—C (green), E (blue), E+P (red), and P (gray)—
with E3 metastases in distant organs without (C) or with E, P, or E+P restoration. Data are presented as mean percentages per group. (C)
Immunohistochemistry (IHC) for CK8/18, ER, PR, and CK5 in organs with E3 micrometastases (C) and macrometastases (E or E+P). For percentage
of CK5+ cells, mean ± SEM values are shown (n = 3 per group). Scale bars: 50 μm. (D) IHC for CK8/18 and nuclear proliferation marker (Ki67) in
organs with E3 or MCF-7 micrometastases (C) and macrometastases (E+P). For percentage of Ki67+ cells, mean ± SEM values are shown
(n = 3 per group). Scale bars: 50 μm.
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cence, organs were sectioned and stained with H&E.
This confirmed the presence of macrometastases in
multiple organs of E- or E+P-replete mice, most com-
monly in lungs, brain, adrenals, LNs, abdomen, kidney,
and uterus (Figure 4B). (Organs with macrometastases
often had micrometastases in adjacent regions.) C or P
mice showed few if any metastases in random H&E-
stained sections of similar organs (Figure 4B).
To explain how luminal metastases could arise in C
mice that appeared to be metastases-free prior to hor-
mone resumption, we reasoned that one or more organs
must have harbored micrometastases that had escaped
detection because of random sectioning or fluorescence
below the limits of detection. We therefore returned to
E3-injected C mice necropsied at 16 weeks, and system-
atically serial-sectioned select entire organs, immuno-
staining every 10th 4 μm section for the luminal marker
CK8/18. This marker detects micrometastases—defined
as fewer than 100 cells—more effectively than H&E. We
found CK8/18+ micrometastases in adrenal glands, uteri,
and mammary gland LNs of C mice (Figure 4C). For
comparison, CK8/18+ E3 macrometastases in mammary
gland LNs of E- and E+P-treated mice are also shown
(Figure 4C). Apparently metastases-free C mice injected
with MCF-7 cells also harbored CK8/18+ micrometas-
tases in adrenal glands, which are compared with CK8/
18+ MCF-7 macrometastases in adrenal glands of E-
and E+P-treated mice (Additional file 9A).
To contrast molecular markers of micro- versus
macrometastases, sections adjacent to CK8/18+ ones
were immunostained for ER, PR, and CK5. Control E3
micrometastases were surprisingly PR− and also CK5−
(Figure 4C). MCF-7 micrometastases were PR− with
about 9% CK5+ cells (Additional file 9A). E3 macrome-
tastases, derived from hormone-treated mice, were ER+,
strongly PR+ with about 14 (E) or 27% (E+P) CK5+ cells
(Figure 4C). Similarly, E- or E+P-treated MCF-7 macro-
metastases were ER+, PR+, and CK5+ (Additional file 9A).
Of note, PR+ and CK5+ heterogeneity are restored or
enhanced in dormant tumors reactivated by hormones
in both E3 and MCF-7 adrenal and LN metastases(Additional file 9B). As described for bone metastases
(Figure 3D), the CK5+ luminobasal subpopulation is mark-
edly growth-suppressed compared with its CK5− neigh-
bors (Additional file 9C).
To contrast proliferation rates between macro- and
micrometastases, Ki67 was quantified (Figure 4D); 35%
to 37% of adrenal or mammary gland LN E+P-treated E3
macrometastatic cells were proliferating, compared with
0% to 4% of similar micrometastatic cells (Figure 4D).
Thus, E3 micrometastases are functionally dormant as
defined clinically [37,38]. MCF-7 cells are more prolifer-
ative even as micrometastases with about 20% Ki67+
cells (Figure 4D), which may explain their more aggres-
sive behavior (compare Figure 1A with Figure 1D).
Overall, these data demonstrate that, even in the ab-
sence of hormones, luminal tumor cells disseminated
through the circulation can, and do, implant and survive
at metastatic sites; that entry into “dormancy” varies
among tumors (as it does here for T47D-derived versus
MCF-7 cells) making some less perilous than others; and
that some cells enter a state of proliferative stasis from
which they can escape if E or E+P is restored. The clinical
implications are grave with regard to hormone supple-
mentation for women who are breast cancer survivors or
have occult disease.
Discussion
Models
Though considered a stringent “intrinsic” molecular sub-
type definable by presence of steroid receptors, luminal
breast cancer is a complex disease. Among other vari-
ables, tumors that are ER+PR+, ER+PR− or ER−PR+,
HER2− or HER2+, or low- or high-grade are all classified
as luminal [39,40]. Tumors that may have initiated years
or decades earlier are diagnosed in the pre-, peri-, and
post-menopausal years, each with the attendant hormonal
changes that differ from woman to woman. Until recently,
clinical assays, including gene expression profiling, assessed
the bulk of a breast cancer to assign its subtype. However,
such assays cannot define intratumoral cell heterogeneity
[41]. IHC analyses clearly demonstrate that invariably, indi-
vidual luminal tumors consist of cell mixtures, only one of
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we use IHC to examine the role of ovarian hormones in lu-
minal breast cancer metastasis by using four experimental
cells: two luminal and two basal. Like their clinical coun-
terparts, the models are variable: MCF-7 are ER+ but need
estradiol to induce PR; T47Dco and their E3 derivatives
are ER+ with partially constitutive elevated PR. Both are
CK5−. EWD8, also derived from T47Dco, is ER−PR− and
CK5+; MDA-MB-231 is basal-like and CK5−. We describe
a role for hormones in development of luminal metastases,
the cellular heterogeneity of micro- and macrometastases
arising from apparently homogeneous cell models, a PR−
dormant state that may be a sanctuary from therapies, and
a role for hormones in escape from dormancy. To the best
of our knowledge, these observations are novel.
The cellular heterogeneity is clearly demonstrable with
just two markers—PR and CK5—that theoretically gener-
ate four possible cell types: luminal PR+CK5−, luminobasal
PR−CK5+, double-negative PR−CK5−, and double-positive
PR+CK5+. To various degrees, we observe all four in clin-
ical and model luminal disease. It is not unreasonable to
postulate that, if more markers were analyzed, even
greater heterogeneity would be observed, ultimately
demonstrating that every single luminal tumor is unique
in its cellular composition and therapy vulnerability.
This has clear implications for disease management.
Hormones promote metastasis of ER+PR+ cells
As has been elegantly demonstrated, metastasis requires
completion of a complex series of steps, including escape
of tumor cells from the primary site into surrounding tis-
sues, their survival and transport via lymphatics and blood
vessels, and their capture and expansion in distant organs
[33]. We previously showed that xenografted solid luminal
tumors efficiently metastasize to local and distant LNs
[21]. On the other hand, compared with basal tumors, lu-
minal tumor metastasis to distant organs is highly ineffi-
cient, requiring months of observation [42] and risking
premature mouse attrition. Xenograft tumor volumes that
are achieved in 20 to 30 days with basal cells require 150
to 200 days with luminal cells. Therefore, to design studies
in which hormone supplementation is the major variable
and in which different cell subpopulations can be ana-
lyzed, we used IC injection, which circumvents the first
steps in the metastasis cascade. Under these conditions,
basal metastases were quantifiable in 20 to 30 days; lu-
minal metastases in 40 to 80 days (Figure 1). Parenthetic-
ally, these numbers suggest that a major impediment to
experimental studies of luminal metastases from solid tu-
mors is the early local invasion and intravasation steps
[33] but that once tumor cells are in the blood, later
events unfold rapidly regardless of tumor subtype.
Based on our experience and that of others [43], these
early steps cannot be hastened by hormones. On theother hand, the present studies show for the first time
that for receptor-positive luminal cells, the later steps
are hormone-dependent. Compared with basal-like MDA-
MB-231 and EWD8 cells, which metastasize efficiently in
ovx’d mice with or without hormones, luminal E3 and
MCF-7 cells do so mainly if hormones are restored. Estro-
gens appear to be key. Effects of P are variable, amplifying
the E-dependent metastasis rate of E3 cells (Figure 1A) but
failing to do so for MCF-7 cells (Figure 1D). This is an-
other example of luminal tumor variability. These data val-
idate the clinical practice of using adjuvant therapies that
suppress E production or ER signaling to slow develop-
ment of luminal metastases [7]. However, such preventive
strategies would fail for the ER−PR−CK5+ luminobasal sub-
populations commonly found in luminal disease [22,23].
This may explain why, compared with ER+PR+ primary tu-
mors, ER tumors are lost in about 25% of metastases and
PR tumors are lost at an even greater rate [44,45] and sug-
gests that adjuvant combination therapies that target both
cell types might be extremely effective. However, chemo-
therapies are unlikely to work since luminobasal cells are
quiescent when mixed with luminal cells (Figure 3D and
Additional file 9C) [23].
Hormones promote luminal metastases at multiple
organs
Luminal and basal cells tend to colonize the same or-
gans: bones, liver, lungs, brain, and adrenals (Figure 2
and Additional file 4). The same sites are colonized in
patients regardless of breast tumor subtype [46]. How-
ever, this tends to be hormone-dependent for ER+PR+
luminal cells and hormone-independent for ER−PR− basal
cells, suggesting that the exogenous hormones target the
malignant cells directly. Of course, the metastatic niche
may also be targeted by hormones [47]. Additionally,
some organs, like adrenals and brain and tissues like fat,
are capable of endogenous E and P biosynthesis [31]. Such
extragonadal hormone production increases with age [48],
which might drive the slow but eventual development of
experimental luminal metastases from solid tumor xeno-
grafts in rodents or hormone-dependent metastases in
postmenopausal women. Significantly, in women, no life
stage is entirely depleted of ovarian hormones.
Heterogeneity of metastases from pure luminal progenitors
The origins of intratumoral heterogeneity remain under
intense debate. Explanations include differentiation from
cancer stem cells, clonal expansion of intrinsic subpopu-
lations, microenvironmental selection, random muta-
tions creating genetic diversity, and epigenetic switches
[33,41]. It is likely that at one time or other all of these
come into play. The present data focus on bone metasta-
ses, although heterogeneity is observed in other sites as
well (Additional file 8; data not shown). In our studies,
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minal cells (Additional file 2), their metastases are
heterogeneous (Figure 3 and Additional file 6). E3 me-
tastases contain about 8% ER−PR− luminobasal cells in
E-supplemented mice and about 18% luminobasal cells
in E+P-supplemented mice (Figure 3C) consistent with
the fact that P induces luminobasal cells [11]. Remark-
ably, although the injected parental MCF-7 cells appear
to be uniformly CK5−, there is considerable intratumoral
heterogeneity in their metastases with 25% to 30% of cells
ER−PR−CK5+ in E or E+P conditions (Figure 3C). Since
the injected cells were homogeneous (Additional file 2),
the heterogeneity had to arise within the metastatic
niche and hormones play a role in inducing heterogen-
eity (Additional file 5). However, we cannot rule out that
rare non-luminal rogue cell variants or stem cells were
contained in the parental cells at the time of injection. It
is also difficult at present to dissect out whether hormones
generate the diversity (versus simply being growth-
permissive for some but not all subpopulations).
Dormant luminal tumors: sheltered from therapies and
activated by hormones
Tumor dormancy is well documented with luminal dis-
ease having a propensity to recur even decades after first
diagnosis [37,49,50]. Anatomical compartments in which
minimal residual disease have been detected include bone
marrow, LNs, and blood [49], where, it is postulated, the
tumor mass remains microscopic by evading immune sur-
veillance or failing to recruit a vascular bed [49,50]. Al-
though there are limitations to the methods we use to
detect micrometastases, we find dormant luminal micro-
metastases in some organs of control ovx’d mice. Microme-
tastases appear to have a different molecular composition
than their macromolecular counterparts. Interestingly, both
E3 and MCF-7 micrometastases are ER+PR− (Figure 4C
and Additional file 9A). This could have serious conse-
quences since loss of PR is a poor prognostic factor in ER+
breast cancers and plays a role in tamoxifen resistance
[51-53]. We postulate that PR negativity, coupled with in-
trinsic mitotic quiescence of the CK5+ subpopulation,
shelters dormant luminal micrometastases from most
current therapies.
We also show a role for women’s hormones in luminal-
tumor arousal from dormancy (Figure 4). Of interest is
the fact that all proposed dormancy mechanisms focus on
the metastatic site (rather than the primary site), making
our models particularly relevant [37,49]. Since NSG mice
are immunodeficient, emergence from dormancy after
hormone replacement is unlikely to involve immune
mechanisms [49]. On the other hand, angiogenesis could
play a role [37,49]. Either cells in the metastatic niche or
the ER+ tumor cells residing therein could be targets of
hormones that, among other things, upregulate hypoxiainducible factor-1, VEGF, and other factors involved in
vasculogenesis [47,54,55]. In the latter scenario, the
hormone-activated luminal tumor cells would be direct
participants in expanding the vasculature that supports
their growth.
Conclusions
We compare luminal and basal-like breast cancer cells
for their propensity to develop metastases or undergo
dormancy prior to resuming metastatic growth; show that
for luminal cells, both processes are hormone-dependent;
and suggest that dormant luminal cells may be sheltered
from therapies and that, compared with the injected cells,
their metastases contain variant cell subpopulations.
Translated to the clinic, these data explain, on the one
hand, the value of adjuvant E-suppressive therapies and
even chemotherapies to delay metastases but perhaps
their failure eventually to prevent metastases from previ-
ously disseminated cells. The data also point to the danger
of initiating hormone replacement therapies in breast
cancer survivors who may harbor occult, dormant micro-
metastases. Furthermore, about 9% of women who have
never had a diagnosis of breast cancer have undiagnosed
occult invasive disease or ductal carcinoma in situ at the
time of death from other causes [56]. This microdisease
reservoir also could be inadvertently activated by hor-
mones [15].
Additional files
Additional file 1: List of reagents and antibodies.
Additional file 2: Immunohistochemistry (IHC) of three-dimensional
(3D) colonies formed from luminal estrogen receptor-positive/
progesterone receptor-positive (ER+PR+) and basal-like ER−PR− cell
lines prior to intracardiac (IC) injections. E3, MCF-7, estrogen
withdrawn-line 8 (EWD8), and MDA-MB-231 cells were grown as 3D
Matrigel colonies and processed for IHC. Sections underwent dual
immunofluorescent staining for cytokeratin 5 (CK5) (red), ER, PR, or
vimentin (green) and were counterstained with 4′,6-diamino-2-
phenylindole (DAPI) (blue). Images are representative of three independent
cultures. Scale bars: 20 μm.
Additional file 3: Body weights of mice during observation for
development of metastases (A). Total body weights were measured
weekly for ovariectomized (ovx’d) mice intracardiac (IC)-injected with
estrogen withdrawn-line 8 (EWD8) or E3 cells treated with control (C),
estrogen (E), or estrogen + progestin (E+P) for 80 days. Data are
presented as mean ± standard error of the mean (SEM) (n = 20 per
group). (B) Total body weights were measured weekly for ovx’d mice
IC-injected with MCF-7 cells treated with C, E, or E+P for about 40 days.
Data are presented as mean ± SEM (n = 20 per group).
Additional file 4: Hormonal regulation of MCF-7 and MDA-231 cell
metastases. (A) Bar graph shows the percentage of mice in each
treatment group—control (C) (green), estrogen (E) (blue), and estrogen +
progestin (E+P) (red)—with MCF-7 metastases to distant organs. Data are
presented as mean percentages per group (n = 20 per treatment group).
(B) Bar graph shows the percentage of mice in each treatment group—C
(green), E (blue), and E+P (red)—with MDA-231 metastases to distant
organs. Data are presented as mean percentages per group (n = 10 per
treatment group). (C) Number of ZsGreen-positive (ZsG+) metastatic sites
per mouse intracardiac (IC)-injected with MCF-7 or MDA-MB-231 cells in
Ogba et al. Breast Cancer Research  (2014) 16:489 Page 12 of 14C, E, or E+P states. Data are presented as mean ± standard error of the
mean (SEM) (n = 20 per group for MCF-7; n = 10 per group for MDA-231).
**P <0.005, Student’s t test.
Additional file 5: Hormones increase the number of cytokeratin
5-positive (CK5+) cells in three-dimensional (3D) luminal colonies.
(A) E3 cells were grown as 3D colonies in phenol red-free growth
factor-reduced Matrigel and treated with control (ethanol, 1:1,000 vol/
vol), 10 nM estrogen (E), or 100 nM progestin (P) for 1 week. Percentages
of CK5+ cells are presented as mean ± standard error of the mean (SEM)
values. Scale bars: 50 μm. (B) MCF-7 cells were grown as 3D colonies in
phenol red-free growth factor-reduced Matrigel and treated with control,
10 nM E, and 100 nM P for 1 week. Percentages of CK5+ cells are
presented as mean ± SEM values. Scale bars: 50 μm. Both images are
representative of three independent experiments.
Additional file 6: Immunohistochemistry (IHC) of luminal E3 or
MCF-7 bone metastases showing heterogeneity for receptors and
cytokeratin 5 (CK5), plus other markers. (A) Ovariectomized (Ovx’d)
mice were intracardiac (IC)-injected with E3 cells and treated with control
(C), estrogen (E), or estrogen + progestin (E+P). IHC: Bone sections were
stained for CK8/18, CLD3, or HER2 (green); CK5 (red); and 4′,6-diamino-2-
phenylindole (DAPI) counterstain (blue). Representative images are
shown (n = 4 per group). BT474 and MDA-MB-231 cells were used as
positive controls for HER2 or vimentin. Scale bars: 20 μm. (B) Ovx’d mice
were IC-injected with MCF-7 cells and treated with C, E, or E+P. IHC: Bone
sections were stained for CK8/18 or HER2 (green), CK5 (red), and DAPI
(blue). Representative images are shown (n = 3 per group). BT474 and
MDA-MB-231 cells were used as positive controls. Scale bars: 20 μm.
Additional file 7: Heterogeneity of marker expression in basal-like
estrogen withdrawn-line 8 (EWD8) or MDA-231 bone metastases.
(A) Representative hematoxylin and eosin (H&E) and immunohistochemistry
(IHC) of EWD8 or MDA-MB-231 bone metastases in mice treated with
control (C), estrogen (E), or estrogen + progestin (E+P). H&E: bone (B), tumor
(T). Scale bars: 50 μm. IHC: Dual staining for ER, PR, or vimentin (green), CK5
(red), and 4′,6-diamino-2-phenylindole (DAPI) (blue) is indicated (n = 5 per
group). Scale bars: 20 μm. (B) Proliferation rate of luminobasal (LB) ER+PR
+CK5+ and double-negative (DN) ER−PR−CK5− subpopulations measured
with phosphor-histone H3 (pHH3) in C, E, and E+P-treated EWD8 bone me-
tastases. Mean ± standard error of the mean (SEM) values are shown (n = 4
per group). **P <0.005, Student’s t test.
Additional file 8: Heterogeneity of luminal brain metastases.
(A) Hematoxylin and eosin (H&E) and immunohistochemistry (IHC) of E3
and MCF-7 brain metastases in mice treated with control (C), estrogen
(E), or estrogen + progestin (E+P). H&E: Tumor-free or normal brain (N),
tumor cells (T). Scale bars: 50 μm. IHC: Dual staining for progesterone
receptor (PR) or cytokeratin 8/18 (CK8/18) (green), CK5 (red), and 4′,6-
diamino-2-phenylindole (DAPI) (blue) (n = 3 per group). Scale bars: 20 μm.
(B) Paraffin sections of brain metastases from a patient with luminal
breast cancer; dual colorimetric staining for CK5 (pink) and PR (brown).
Scale bars: 20 μm.
Additional file 9: Hormones increase progesterone receptor (PR)
and cytokeratin 5 (CK5) expression in MCF-7 macrometastases, but
CK5+ cells are relatively quiescent. (A) Immunohistochemistry (IHC) for
CK8/18, estrogen receptor (ER), PR, and CK5 in MCF-7 adrenal gland
micrometastases formed in the absence of hormones (C), versus
macrometastases formed with estrogen (E) and estrogen + progestin
(E+P). Percentages of CK5+ cells are presented as mean ± standard error
of the mean (SEM) values (n = 3 per group). Scale bars: 50 μm. (B) IHC for
ER or PR (green), CK5 (red), and 4′,6-diamino-2-phenylindole (DAPI) (blue)
of E3 and MCF-7 macrometastases in adrenals or LNs (n = 5 per group).
Scale bars: 20 μm. (C) Proliferation rates of CK5+ and CK5− cells measured
by phosphor-histone H3-positive (pHH3+) in E+P-treated E3 or MCF-7
adrenal (adr.) gland and LN metastases aroused from dormancy. Mean ±
SEM values are presented (n = 3 per group). **P <0.005, Student’s t test.
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